What does MDxHealth do and what are its main business segments?

What factors drove the changes in MDxHealth's revenue and profit?

What is MDxHealth's latest dividend and current dividend yield?

What were the key takeaways from MDxHealth’s earnings call?

What guidance did MDxHealth's management provide for the next earnings period?

What were the key takeaways from MDxHealth's earnings call?

What is the market's earnings forecast for MDxHealth next quarter?

What is the revenue and EPS growth rate for MDxHealth year over year?

- **Revenue Growth**: Q3 2025 revenue $27.4M (+18% YoY), driven by tissue-based tests (76% of revenue) and liquid-based growth (65% YoY).
- **ExoDx Acquisition**: $20+M 2026 contribution expected, offsetting Germline de-emphasis.
- **Profitability**: Gross margin 65.2% (vs 61.2% Q3 2024), positive EBITDA $1M.
- **Execution**: 60 sales reps, seamless customer conversion to ExoDx, operational efficiency improvements.

**【CEO Summary Section】**
- Q3 2025 revenue of $27.4 million, up 18% YoY, driven by tissue-based tests (76% of revenue) and liquid-based growth (65% YoY). 
- ExoDx acquisition completed in Q3, with integration prioritized for Q4, including 10 new sales reps and territory adjustments.
- Germline test de-emphasized in Q4 to focus on ExoDx integration, maintaining 2025 revenue guidance of $108-110 million.
- Gross margin improved to 65.2% (vs 61.2% Q3 2024), driven by test mix and operational efficiency.
- Adjusted EBITDA positive $1 million vs -$3.8 million Q3 2024, with cash use under $1 million.

**【CFO Financial Commentary】**
- Q3 GAAP net loss $8 million (down 28% YoY), operating loss $2.6 million (down 57% YoY).
- Total billable volume 33,000 tests (18% tissue growth, 65% liquid growth).
- Non-GAAP EPS exceeds expectations, with strong cost control and OpEx flat YoY.

**【Q&A Highlights】**
- ExoDx expected to contribute $20+ million in 2026, offsetting Germline de-emphasis.
- Gross margin expected to remain above 65% with ExoDx accretive to margins.
- Sales force expansion to 60 reps (from 50) with focus on cross-selling opportunities.
- Customer conversion from Select to ExoDx seamless, with ExoDx superior clinical utility.

MDxHealth SA (MDXH) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

MDXH

MDXH fundamentals

You can ask Aime